Hormonal
Liraglutide (3.0 mg once daily) combined with lifestyle changes is an effective treatment for obesity in patients with and without type 2 diabetes, resulting in significant weight loss and maintenance.
Liraglutide 3.0 mg taken once daily, combined with lifestyle changes, is an effective treatment for obesity in adults with or without type 2 diabetes. It leads to significant weight loss (average ~7.8% in some trials) and helps maintain weight loss, with benefits extending to clinical comorbidities.
Furthermore, liraglutide (3.0 mg) as a medication for the treatment of obesity, in association with lifestyle changes, in patients with and without diabetes proved to be a good therapeutic option with a response about weight loss and maintenance, in addition to benefits secondary to clinical comorbidities associated with obesity.
Why this rating
Supported by multiple RCTs (SCALE, SCALE Diabetes, etc.) included in the review.
Source
Major clinical outcomes of the action of the co-agonist tirzepatide to liraglutide and semaglutide in the treatment of obesity and type 2 diabetes mellitus: a systematic review
Helena Ramalho Arvate · International Journal of Nutrology · 2025
DOI 10.54448/ijn25102
More from this paper
- Tirzepatide (5-15 mg once weekly) produces superior weight loss (16.5% to 22.4%) and glycemic control compared to GLP-1 monotherapies (liraglutide, semaglutide) and other glucose-lowering medications in patients with type 2 diabetes and obesity.Good
- Semaglutide (≥0.2 mg once weekly) demonstrates statistically significant weight loss compared to liraglutide 3.0 mg in patients with obesity without diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →